Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
97 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016', provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome - The report reviews pipeline therapeutics for Acute Respiratory Distress Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Acute Respiratory Distress Syndrome therapeutics and enlists all their major and minor projects - The report assesses Acute Respiratory Distress Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Acute Respiratory Distress Syndrome Overview 9 Therapeutics Development 10 Pipeline Products for Acute Respiratory Distress Syndrome - Overview 10 Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis 11 Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies 12 Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes 13 Acute Respiratory Distress Syndrome - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Acute Respiratory Distress Syndrome - Products under Development by Companies 17 Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes 18 Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development 19 Altor BioScience Corporation 19 Athersys, Inc. 20 Faron Pharmaceuticals Oy 21 FirstString Research, Inc. 22 GlaxoSmithKline Plc 23 Global Blood Therapeutics, Inc. 24 Hydra Biosciences, Inc. 25 Phylogica Limited 26 S-Evans Biosciences, Inc. 27 Savara Inc. 28 Silence Therapeutics Plc 29 Acute Respiratory Distress Syndrome - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 ALT-836 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 BIO-10901 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 BIO-11006 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 GBT-440 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 GSK-2586881 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 GSK-2862277 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 HC-067047 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 interferon beta-1a - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 LT-0011 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 molgramostim - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 PF-05285401 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 PYC-35 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 PYC-36 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 PYC-38 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 PYC-98 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 S-1229 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 SAN-101 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Acute Respiratory Distress Syndrome - Dormant Projects 83 Acute Respiratory Distress Syndrome - Discontinued Products 86 Acute Respiratory Distress Syndrome - Product Development Milestones 87 Featured News & Press Releases 87 May 25, 2016: First patient dosed in Savaras pivotal trial for PAP 87 Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation 87 Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS 88 Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome 88 Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP 89 Aug 09, 2015: Serendex to initiate first phase II clinical trial 90 Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November 90 May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced 91 May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical's inhalable biological drug for treatment of severe pulmonary diseases 91 May 10, 2015: Positive topline data from Serendex phase I clinical trial 92 Feb 27, 2015: Serendex submits phase I application 93 Feb 13, 2015: Serendex partners up with leading German lung center 93 Jan 28, 2015: Serendex receives positive scientific advice from EMA 94 Jan 22, 2015: Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition 94 Dec 10, 2014: Serendex Registers First Sale Of Molgradex 95 Appendix 96 Methodology 96 Coverage 96 Secondary Research 96 Primary Research 96 Expert Panel Validation 96 Contact Us 96 Disclaimer 97
List of Tables
Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2016 10 Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Number of Products under Investigation by Universities/Institutes, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Investigation by Universities/Institutes, H2 2016 18 Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corporation, H2 2016 19 Acute Respiratory Distress Syndrome - Pipeline by Athersys, Inc., H2 2016 20 Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2 2016 21 Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H2 2016 22 Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016 23 Acute Respiratory Distress Syndrome - Pipeline by Global Blood Therapeutics, Inc., H2 2016 24 Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences, Inc., H2 2016 25 Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H2 2016 26 Acute Respiratory Distress Syndrome - Pipeline by S-Evans Biosciences, Inc., H2 2016 27 Acute Respiratory Distress Syndrome - Pipeline by Savara Inc., H2 2016 28 Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H2 2016 29 Assessment by Monotherapy Products, H2 2016 30 Number of Products by Stage and Target, H2 2016 32 Number of Products by Stage and Mechanism of Action, H2 2016 34 Number of Products by Stage and Route of Administration, H2 2016 36 Number of Products by Stage and Molecule Type, H2 2016 38 Acute Respiratory Distress Syndrome - Dormant Projects, H2 2016 83 Acute Respiratory Distress Syndrome - Dormant Projects (Contd..1), H2 2016 84 Acute Respiratory Distress Syndrome - Dormant Projects (Contd..2), H2 2016 85 Acute Respiratory Distress Syndrome - Discontinued Products, H2 2016 86
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
